---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-011915"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2023-04-05T23:59:59+00:00"
generated_at: "2026-06-17T05:58:35.189574+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Surrozen appoints Eric Bjerkholt as Class I director and audit committee member

## Summary
- Eric Bjerkholt appointed to board as Class I director effective April 5, 2023.
- He will serve on the audit committee.
- Bjerkholt is CFO of Chinook Therapeutics; previously CFO of Aimmune, leading its $2.6B sale to Nestle.
- Compensation: $35,000 annual retainer, $7,500 audit retainer, initial option grant of 40,000 shares vesting over 36 months.
- Standard indemnification agreement entered with Bjerkholt.

## SEC filing metadata
- accession: 0000950170-23-011915
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2023-04-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017023011915/0000950170-23-011915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017023011915/srzn-20230405.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-011915
- JSON: https://secwatch.observer/filing/0000950170-23-011915.json
- Plain text: https://secwatch.observer/filing/0000950170-23-011915.txt

## Key facts
- Executive change
  Eric Bjerkholt was appointed as Class I Director at Surrozen, Inc./DE.
  - Action: appointed
  - Role: Class I Director
  source text: On April 5, 2023, the board of directors of Surrozen, Inc. appointed Eric Bjerkholt to serve as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824893/000095017023011915/0000950170-23-011915-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.